URGN — UroGen Pharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1668243 ·
Last close
$29.46
Market Cap
$1.44B
52W High
$32.37
52W Low
$16.50
ADV30
916,837
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 50,959,000 | 46,820,000 | -20,263,000 | -23,574,000 | 253,690,000 | 109,968,000 | 377,943,000 |
| Dec 2025 | 37,837,000 | 34,548,000 | -19,115,000 | -26,364,000 | 200,455,000 | 110,745,000 | 305,929,000 |
| Sep 2025 | 27,482,000 | 24,204,000 | -27,386,000 | -33,347,000 | 185,046,000 | 90,039,000 | 300,454,000 |
| Jun 2025 | 24,215,000 | 20,665,000 | -41,448,000 | -49,940,000 | 208,717,000 | 92,904,000 | 302,093,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-162,444,000
Investing CF
$61,558,000
Financing CF
$39,918,000
CapEx
$-289,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.20
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-959,716,000
Inventory
$16,464,000
Receivables
$33,082,000
ST Investments
$9,711,000
EBIT TTM
$-138,071,000
Pretax Income TTM
$-153,416,000
Interest Exp TTM
$15,345,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$140,492,992
EBITDA
$-107,902,000
Free Cash Flow
$-109,282,248
Enterprise Value
$1,492,160,256
Total Cash
$140,274,000
Total Debt
$197,092,992
Shares Out
48,721,701
Trailing EPS
$-2.74
Book Value
$-2.55
ROE
—
ROA
-27.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 109,788,000 | -124,863,000 | -153,494,000 | 200,455,000 | 305,929,000 | — | -162,444,000 |
| Dec 2024 | 90,398,000 | -96,782,000 | -126,874,000 | 285,711,000 | 294,514,000 | — | -96,766,000 |
| Dec 2023 | 82,713,000 | -65,536,000 | -102,244,000 | 178,311,000 | 243,523,000 | — | -76,376,000 |
| Dec 2022 | 64,357,000 | -79,041,000 | -109,783,000 | 135,619,000 | 224,980,000 | — | -87,559,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.44
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KALV | KalVista Pharmaceuticals, Inc. | $1.43B | $26.81 | — |
| BCAX | Bicara Therapeutics Inc. | $1.44B | $21.98 | — |
| SEPN | Septerna, Inc. | $1.38B | $30.65 | — |
| PRGO | PERRIGO Co plc | $1.49B | $10.80 | — |
| SLS | SELLAS Life Sciences Group, Inc. | $1.51B | $8.12 | — |
News headlines (Yahoo Finance, 1h cache)
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
2026-05-23 22:40 · Yahoo
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
2026-05-23 22:33 · Yahoo
How UGN-103’s Strong Phase 3 UTOPIA Data Could Shape UroGen Pharma (URGN) Investors
2026-05-21 21:18 · Yahoo
Sector Update: Healthcare Stocks Gain Late Afternoon
2026-05-19 19:55 · Yahoo
UroGen Pharma Investor Event Reinforced Zusduri Commercial Thesis, Oppenheimer Says
2026-05-19 14:55 · Yahoo
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
2026-05-15 12:00 · Yahoo
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
2026-05-13 12:00 · Yahoo
Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
2026-05-11 13:55 · Yahoo
Assessing UroGen Pharma (URGN) Valuation After Q1 2026 Earnings Beat And Zusduri Launch Momentum
2026-05-09 03:18 · Yahoo
UroGen (URGN) Q1 2026 Earnings Transcript
2026-05-07 16:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.